基于网络药理学的肝力保胶囊保肝作用机制研究

陈俊; 陈青山; 孙森; 赵亮; 张海; 张国庆; 陈俊; 陈青山; 孙森; 赵亮; 张海; 张国庆

doi:10.3969/j.issn.1006-0111.2018.05.005

[1]

王慧, 李洋, 周燕妮, 等. HPLC法同时测定肝力保胶囊中绿原酸及虎杖苷的含量[J]. 解放军药学学报,2015,31(4):338-340.

[2]

王慧, 路克军, 张国庆. 高效液相色谱法测定肝力保胶囊中苦参碱及槐定碱的含量[J]. 第二军医大学学报,2012,33(11):1267-1269.

[3]

李洋, 王慧, 吕磊,等. HPLC-TOF/MS对肝力保胶囊化学成分的快速鉴别[J]. 中国实验方剂学杂志,2015:70-73.

[4]

KIBBLE M, SAARINEN N, TANG J, et al. Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products[J]. Nat Prod Rep,2015,32(8):1249-1266.

[5]

ZHAO S, IYENGAR R. Systems pharmacology:network analysis to identify multiscale mechanisms of drug action[J]. Annu Rev Pharmacol Toxicol,2012,52:505-521.

[6]

LI S, ZHANG B. Traditional Chinese medicine network pharmacology:theory, methodology and application[J]. Chin J Nat Med,2013,11(2):110-120.

[7]

李刚, 许波, 梁学振,等. 基于网络药理学研究淫羊藿抗骨质疏松的分子机制[J]. 中国药理学通报,2018(2):267-273.

[8]

冯燕燕, 谢媛媛, 汪艳平, 等. 基于"药物-靶点-通路"网络的血必净注射液治疗脓毒症分子调控机制[J]. 药学学报,2017,52(4):556-562.

[9]

王珂欣, 高丽, 周玉枝, 等. 基于网络药理学的苦参碱抗肝癌作用及机制研究[J]. 药学学报,2017,52(6):888-896.

[10]

蒋园, 白云, 刘萍, 等. 黄芪甲苷对CCl₄所致小鼠肝损伤的影响[J]. 中药药理与临床,2015,31(6):24-27.

[11]

张雅雯, 邵东燕, 师俊玲, 等. 山奈酚生物功能研究进展[J]. 生命科学,2017,29(4):400-405.

[12]

陈剑明, 张声生, 吴震宇, 等. 虎杖苷对非酒精性脂肪肝保护作用的实验研究[J]. 中华中医药学刊,2015,33(5):1188-1191+1294-1295.

[13]

战旗, 李悦悦, 王晓俊, 等. 人血白蛋白在原发性肝癌肝切除术后的应用分析[J]. 药学实践杂志,2015,33(5):463-466.

[14]

GARCIA-MARTINEZ R, CARACENI P, BERNARDI M, et al. Albumin:pathophysiologic basis of its role in the treatment of cirrhosis and its complications[J]. Hepatology,2013,58(5):1836-1846.

[15]

ZHAO G, HATTING M, NEVZOROVA YA,et al. Jnk1 in murine hepatic stellate cells is a crucial mediator of liver fibrogenesis[J]. Gut,2014,63(7):1159-1172.

[16]

POLIVKA J Jr,JANKU F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway[J]. Pharmacol Ther,2014,142(2):164-175.

[17]

BRENNER C, GALLUZZI L, KEPP O, et al. Decoding cell death signals in liver inflammation[J]. J Hepatol,2013,59(3):583-594.

[18]

PAN X, ZHANG Y, KIM HG, et al. FOXO transcription factors protect against the diet-induced fatty liver disease[J]. Sci Rep,2017,7:44597.

[19]

DOWNWARD J. Targeting RAS signalling pathways in cancer therapy[J]. Nat Rev Cancer,2003,3(1):11-22.

[20]

SEKI E, PARK E, FUJIMOTO J. Toll-like receptor signaling in liver regeneration, fibrosis and carcinogenesis[J]. Hepatol Res,2011,41(7):597-610.